Diabetic Retinopathy
Conditions
Brief summary
Diabetic retinopathy (DR) is a complication of diabetes in which blood vessels supplying blood to the back of the eye (retina) are dysfunctional. This can lead to an improper supply of oxygen and nutrients to the retinal tissue, or it may trigger the formation of new blood vessels in response to the oxygen/nutrient deficiency. Ultimately affecting the normal vision. There is no known marker that will provide information on the health status of retinal blood vessels. Using highly specialized cells in the blood, this study will try to discover a marker of DR.
Interventions
Blood samples will be collected via venipuncture
Sponsors
Study design
Eligibility
Inclusion criteria
* Ability to cooperate with imaging procedures. * Health status: established type 2 diabetes * No history of panretinal photocoagulation (PRP) * No history of treatment with intravitreal agents for past 12 months
Exclusion criteria
* Previous or current malignancy * Acute or chronic infection (HIV, hepatitis B or C, tuberculosis) * Cerebral vascular accident or cerebral vascular procedure * Current pregnancy * History of organ transplantation * Presence of a graft (to avoid any effect of the graft) * History of previous vitrectomy * Subjects with a history of age-related macular degeneration age-related macular degeneration (AMD), glaucoma, uveitis, and branched or central vein occlusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mRNA and miRNA sequencing of circulating angiogenic cells isolated from study participants | Baseline and change in RNA signature in follow up visit (between 3-5 years) |
| Surface marker expression of inflammatory markers using flow cytometry | Baseline |
| miRNA expression | Baseline |
| Epigenetic changes in circulating angiogenic cells with different severities of diabetic retinopathy | Baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Early Treatment Diabetic Retinopathy Study (ETDRS) clinical scoring in wide-field fundus photography | Baseline and follow up visit (between 3-5 years) | The scoring will be between 10 (no retinopathy) and 85 (advanced proliferative diabetic retinopathy). Higher score means worst outcome |
| Presence or absence of neovascularization and total area of non-perfusion in fluorescein angiography (FA) | Baseline and follow up visit (between 3-5 years) | — |
| Change in vessel density in optical coherence tomography angiography (OCT-A) | Baseline and follow up visit (between 3-5 years) | — |
| Change in retinal thickness in optical coherence tomography angiography (OCT-A) | Baseline and follow up visit (between 3-5 years) | — |
Countries
United States